Health care software firm RealMed Corp. will keep its base of operations in Indianapolis after being acquired by health information exchange provider Availity LLC of Jacksonville, Fla. Terms of the deal announced Wednesday were not disclosed.
The U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly’s request to prevent sales until the court rules on a judge’s decision invalidating a patent on the medicine.
The health reform debate may have ended in Congress, but Eli Lilly and Co. remains active, sponsoring a talk about the positives of the
bill—and calling for further government efforts to help pharmaceutical research and development.
Health insurers led by WellPoint Inc. are backing Republicans with campaign donations by an 8-to-1 margin, favoring the party
that’s promised to repeal President Barack Obama’s health-care overhaul if it wins back Congress.
Strattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would
translate into an average $1.22 million in sales.
Venture capitalists in Indiana and nationally have thrown money at the company with abandon. Local investors include CID Capital,
Clarian Health Ventures and the Indiana Future Fund.
Diabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a
groundbreaking Eli Lilly researcher.
Even with debt levels at Eli Lilly and Co. at paltry lows, a string of bad news finally forced Standard & Poor’s
to lower
its rating on the company’s senior unsecured debt. But the New York-based agency said it believes the Indianapolis-based
drugmaker will eventually break its string of bad luck on developing new products.
Two former Eli Lilly and Co. employees launched the firm that promises to attract more clinical trial business to the state.
Outside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis
of studies in lower back pain and osteoarthritis of the knee.
The invalidation of Lilly’s Strattera patent opened the door for as many as 10 companies to sell generic versions of the drug,
which generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder.
The company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet
to be determined.
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta’s
annual sales.
Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
Medco operates an automated pharmacy and distribution center in Whitestown in Boone County, and it plans to employ more than
1,400 people there by 2012.
Changes in reimbursement could fuel market for WoundVision’s product.
Indianapolis-based health care firm reaches agreement to offer its DailyMed product to more WellPoint Inc. health plan members.
Copenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said.
Ascendis may choose a final bidder by early September.
The Batesville-based maker of hospital beds and furniture announced Wednesday night that it earned $30.6 million in its third quarter, up from $20.2 million in the same quarter of 2009.
